AMRN - Amarin Corporation plc
| Previous Close | 3.00 |
| Open | 3.03 |
| Bid | 2.88 x 900 |
| Ask | 2.98 x 1000 |
| Day's Range | 2.85 - 3.08 |
| 52 Week Range | 2.66 - 4.60 |
| Volume | 3,016,856 |
| Avg. Volume | 2,036,917 |
| Market Cap | 845.522M |
| Beta | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.60 |
- Zacks•yesterday
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
Investors in Amarin (AMRN) need to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•11 days ago
Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications
Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co., Ltd. (“Mochida”, TYO:4534), an integrated Japanese pharmaceutical company. The collaboration is focused on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid). Amarin and Mochida are recognized worldwide as the leading, innovation-driven companies committed to the research and development of EPA-based drug products to treat the needs of tens of millions of patients who are at-risk of cardiovascular disease.
- GlobeNewswire•16 days ago
Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, June 07, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•17 days ago
Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diodes ...
- ACCESSWIRE•19 days ago
Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).
- Benzinga•29 days ago
Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24: ArQule, Inc. (NASDAQ: ARQL ) Baxter ...
- GlobeNewswire•last month
Amarin Announces Patent Litigation Settlement Agreement with Teva
BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with Teva Pharmaceuticals USA, Inc. (Teva) that resolves Amarin’s previously reported Vascepa® (icosapent ethyl) patent litigation as it relates to Teva’s abbreviated new drug application seeking U.S. Food and Drug Administration (FDA) approval of generic forms of Vascepa (icosapent ethyl) capsules. This patent litigation continues in the United States District Court for the District of Nevada with parties West-Ward Pharmaceuticals Corp. and Dr. Reddy’s Laboratories, Inc. and their affiliated entities.
- GlobeNewswire•last month
Amarin to Present at the Jefferies Global Healthcare Conference
Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 7, 2018, at 8:00 a.m. EDT. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
- Zacks•last month
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•last month
Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT
Q1 2018 Amarin Corporation PLC Earnings Call
- Associated Press•2 months ago
Amarin: 1Q Earnings Snapshot
The Dublin-based company said it had a loss of 8 cents per share. Losses, adjusted for stock option expense, were 7 cents per share. The results met Wall Street expectations. The average estimate of three ...
- GlobeNewswire•2 months ago
Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations
REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018. Management to Host Conference Call at 7:30 a.m. ET Today. BEDMINSTER, N.J. and DUBLIN, Ireland, May 02, 2018-- Amarin Corporation ...
- Motley Fool•2 months ago
3 Stocks That Could Put Tesla's Returns to Shame
Tesla has made investors a lot of money in recent years. Here are three new stocks we think could do the same for investors going forward.
- GlobeNewswire•2 months ago
Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, April 26, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
- GlobeNewswire•2 months ago
Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer
BEDMINSTER, N.J., and DUBLIN, Ireland, April 23, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•2 months ago
Moving Average Crossover Alert: Amarin (AMRN)
Amarin Corporation plc (AMRN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- GlobeNewswire•2 months ago
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- ACCESSWIRE•3 months ago
Wired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
Stock Monitor: Pernix Therapeutics Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. PLC (NASDAQ: ...
- Motley Fool•3 months ago
Boom-or-Bust News Is On Tap Soon for Amarin
Amarin has needle-moving news that's fast-approaching.
- GlobeNewswire•3 months ago
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
BEDMINSTER, N.J. and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•3 months ago
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
BEDMINSTER, N.J., and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•3 months ago
Implied Volatility Surging for Amarin (AMRN) Stock Options
Surging implied volatility makes Amarin (AMRN) stock lucrative to the option traders.
